Compare FIS & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIS | INSM |
|---|---|---|
| Founded | 1968 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0B | 30.1B |
| IPO Year | 2001 | 2000 |
| Metric | FIS | INSM |
|---|---|---|
| Price | $46.99 | $106.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 24 |
| Target Price | $72.23 | ★ $201.17 |
| AVG Volume (30 Days) | ★ 5.0M | 2.0M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $10,677,000,000.00 | N/A |
| Revenue This Year | $30.41 | $182.31 |
| Revenue Next Year | $4.76 | $65.19 |
| P/E Ratio | $64.29 | ★ N/A |
| Revenue Growth | ★ 5.43 | N/A |
| 52 Week Low | $43.30 | $64.85 |
| 52 Week High | $82.74 | $212.75 |
| Indicator | FIS | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 49.15 | 22.41 |
| Support Level | $46.16 | $101.55 |
| Resistance Level | $51.67 | $166.81 |
| Average True Range (ATR) | 1.26 | 6.15 |
| MACD | 0.11 | -2.15 |
| Stochastic Oscillator | 51.08 | 5.08 |
Fidelity National Information Services provides core processing and ancillary services to banks, but its business has expanded over time. By acquiring SunGard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS was providing payment processing services for merchants and holding leading positions in the United States and United Kingdom. But the company sold off a majority interest in Worldpay and now has only a minority stake.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.